Activity Overview
This online, on-demand virtual symposium brings together renowned experts in atopic dermatitis (AD). In this educational program, these experts discuss the role of the OX40 and OX40 ligand (OX40L) pathway in the development of atopic dermatitis and how this pathway represents a promising therapeutic target for the complex treatment of atopic dermatitis.
This educational activity is an archive of the live symposium held on June 18, 2026.
Target Audience
This educational activity is directed toward health care professionals involved in the management of atopic dermatitis. Specifically, dermatologists, dermatology physician assistants, dermatology nurse practitioners, primary care providers, and nurses are invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the limitations of current therapeutic classes of agents used to manage patients with moderate to severe AD
- Explain the impact of the upstream mechanism of action of OX40-OX40L inhibitors on the inflammatory pathway of AD
- Evaluate clinical trial efficacy and safety data for novel emerging OX40-OX40L inhibitor targeted therapies for the management of moderate to severe AD
Andrew Blauvelt, MD, MBA
Adjunct Professor
Department of Dermatology
University of Maryland School of Medicine
Baltimore, MD
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Eli Lilly, Incyte Corporation, Janssen, Khanda Therapeutics, LEO Pharma, Novartis, Oruka Therapeutics, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB; Ownership interests in publicly traded companies: Lipidio, Oruka Therapeutics
Melinda Gooderham, MD, FRCPC
Medical Director, SKiN Centre for Dermatology
Investigator, Probity Medical Research
Assistant Professor, Queen’s University
Consultant Physician, Peterborough Regional Health Centre
Peterborough, Ontario
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, Apogee Therapeutics, Arcutis Pharmaceuticals, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Dermira, Eli Lilly, Galderma SA, GSK, Incyte Biosciences, JAMP Pharma, Janssen, LEO Pharma, L’Oreal, Merck, MoonLake Immunotherapeutics, Novartis Pharmaceuticals, Oruka Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, UCB, Union Therapeutics, Ventyx, Vyne Therapeutics; Grant/Research Funding: AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Pharmaceuticals, Astraea Therapeutics, Attovia Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, Galderma SA, GSK, Incyte Corporation, Insmed, JAMP Pharma, Janssen, LEO Pharma, L’Oreal, Meiji Seika, Merck, MoonLake Immunotherapeutics, Novartis Pharmaceuticals, Oruka Therapeutics, Pfizer, Q32 Bio, Regeneron Pharmaceuticals, Reistone Biopharma, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, UCB, Ventyx, Vyne Therapeutics
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and
planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
This activity
may have used AI-assisted tools to support educational development. All content
was reviewed and approved by qualified faculty or planners. The accredited
provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
